Missing Information
  • A System Error Has Occured:0018 - Company Information Failed to Load.
Company:  ZIOPHARM ONCOLOGY INC (ZIOP)
CIK:  0001107421 
Address:  ONE FIRST AVENUE
PARRIS BUILDING 34, NAVY YARD PLAZA
 
City, State, Zip:  BOSTON,  02129 
Telephone:  617-259-1970 
Fiscal Year:  12/31 
Last Trade
Last Trade: 
$4.35  
Change: 
-0.16 (-3.55%)  
Trade Time: 
Sep 20  
Market Cap: 
$707.11M
Trade ZIOP now with

© 2019  
Description of Business
We are a biopharmaceutical company focused on discovering, acquiring, developing and commercializing next generation immunotherapy platforms that leverage cell- and gene-based therapies to treat patients with cancer. We are developing two immuno-oncology platform technologies that utilize the patient's immune system by employing novel, controlled gene expression and innovative cell engineering technologies to designed deliver safe, effective, and scalable cell- and viral-based therapies for the treatment of multiple cancer types. Our first platform is referred to as Sleeping Beauty and is based on the genetic engineering of immune cells using a non-viral transposon/transposase system to stably reprogram T cells outside of the body for subsequent infusion.
Register and access this filing in:     
  FORM 10-Q
    Part I - Financial Information
      Item 1. Financial Statements
        BALANCE SHEET
        INCOME STATEMENT
        STOCKHOLDERS EQUITY
        STOCKHOLDERS EQUITY
        CASH FLOW
        NOTES TO FINANCIAL STATEMENTS
      Item 2. Management's Discussion and Analysis of Financial ...
      Item 3. Quantitative and Qualitative Disclosures about ...
      Item 4. Controls and Procedures
    Part II - Other Information
      Item 1. Legal Proceedings
      Item 1A. Risk Factors
      Item 2. Unregistered Sale of Equity Securities and Use of ...
      Item 3. Defaults upon Senior Securities
      Item 4. Mine Safety Disclosures
      Item 5. Other Information
      Item 6. Exhibits
    SIGNATURES
  EXHIBIT 10.3
  EXHIBIT 31.1
    CERTIFICATION
  EXHIBIT 31.2
    CERTIFICATION
  EXHIBIT 32.1
    CERTIFICATION